What was the primary driver of the significant increase in Consumer segment sales?

The primary driver for the substantial 48.5% increase in the Consumer segment's sales was the acquisition of Pfizer Inc.'s Consumer Healthcare business. This acquisition, net of related divestitures, contributed significantly to growth across major franchises, including OTC Pharmaceuticals & Nutritionals and Oral Care Products.

What caused the decrease in Net Earnings despite the sales growth?

The decrease in Net Earnings from $3.305 billion in Q1 2006 to $2.573 billion in Q1 2007 was largely due to an $807 million in-process research and development (IPR&D) charge recognized in the current quarter. This charge is associated with the acquisition of Conor Medsystems, Inc., a cardiovascular device company.

What is the company's stance on ongoing litigation and regulatory matters?

Johnson & Johnson is involved in numerous product liability, patent, and regulatory investigations. While the company acknowledges these matters could have a significant impact on results of operations and cash flows in any given period, management believes that, based on current assessments, the ultimate outcome of these proceedings, net of accrued liabilities, is not expected to have a material adverse effect on the company's financial position.

How has the company's cash position changed, and what is the impact on interest income?

Cash and cash equivalents, along with current marketable securities, decreased significantly to $5.2 billion at the end of Q1 2007, down from $17.2 billion in the prior year. This reduction is primarily attributed to acquisition activities and the 2006 stock repurchase program. Consequently, interest income decreased by $102 million year-over-year due to the lower cash balance.

JNJ 10-Q Quarterly Report Q2 FY2007 — Revenue, Net Income, EPS

Summary

Johnson & Johnson reported a strong first quarter for 2007, with worldwide sales reaching $15.0 billion, a significant increase of 15.7% compared to the same period in the prior year. This growth was driven by broad-based performance across its consumer, pharmaceutical, and medical device segments, with operational growth of 13.3% excluding currency impacts. The company's strategic acquisitions, particularly Pfizer Inc.'s Consumer Healthcare business, played a substantial role in boosting sales, especially within the Consumer segment, which saw a remarkable 48.5% increase. Despite a notable increase in the cost of goods sold as a percentage of sales, the company demonstrated effective cost containment in its pharmaceutical business, contributing to a healthy operating profit margin in that segment.

Key Highlights

1Worldwide sales increased by 15.7% to $15.0 billion in Q1 2007, with operational growth of 13.3%.
2The Consumer segment experienced substantial growth of 48.5%, largely driven by the acquisition of Pfizer Inc.'s Consumer Healthcare business.
3Pharmaceutical segment sales grew by 10.6%, supported by strong performance in anti-psychotics, REMICADE, and TOPAMAX.
4Medical Devices and Diagnostics segment sales increased by 6.2%, though operating profit was impacted by significant R&D charges.
5Net earnings decreased to $2.57 billion ($0.88/share diluted) from $3.31 billion ($1.10/share diluted) year-over-year, primarily due to an $807 million in-process R&D charge related to the Conor Medsystems acquisition.
6The company increased its cash dividend by 13.6% to $0.375 per share, marking the 45th consecutive year of dividend increases.
7Significant litigation and regulatory investigations continue across various product lines, including drug-eluting stents and pharmaceutical products, with management believing these will not materially adversely affect the financial position in the long term.

JOHNSON & JOHNSON Quarterly Report for Q2 Ended Apr 1, 2007

Summary

Key Highlights

Frequently Asked Questions